Nuvalent, Inc. (NUVL)
NASDAQ: NUVL · Real-Time Price · USD
71.03
-3.95 (-5.27%)
Mar 3, 2025, 4:00 PM EST - Market closed
Nuvalent Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
92
Market Cap
5.09B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
NUVL News
- 4 days ago - Nuvalent Outlines Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire
- 7 weeks ago - Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones - PRNewsWire
- 7 weeks ago - Nuvalent: A Logical Acquisition Target - Seeking Alpha
- 2 months ago - Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 3 months ago - Nuvalent Appoints Grant Bogle to Board of Directors - PRNewsWire
- 3 months ago - Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference - PRNewsWire
- 3 months ago - Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results - PRNewsWire
- 5 months ago - Nuvalent: Promising Data Keeps Validating Pipeline And Platform - Seeking Alpha